Abstract
The Human Respiratory Syncytial Virus (hRSV) is a common cause of severe respiratory infections, especially in children, the elderly, and immunocompromised individuals, with high rates of morbidity and mortality. Current treatments, such as Ribavirin and monoclonal antibodies, are limited. The AREXVY vaccine was approved in 2023 but is restricted to the elderly, leaving many vulnerable in…